PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
August 24, 2026The Lancet353 citationsOpen Access

Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials

JBJaved ButlerSSSanjiv J. ShahMPMark C. Petrie

Key Points

Key points are not available for this paper at this time.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Butler et al. (2024) studied this question.

synapsesocial.com/papers/6a8c60a8291a21b80a2e4c76https://doi.org/10.1016/s0140-6736(24)00469-0
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials2016 · 89 citations
  2. 2Effects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling2017 · 215 citations
  3. 3Liraglutide attenuates high glucose-induced abnormal cell migration, proliferation, and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor, and inhibiting ERK1/2 and PI3K/Akt signaling pathways2015 · 90 citations
  4. 4Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care2022 · 142 citations
  5. 5Patients’ Willingness to Accept Mitral Valve Procedure-Associated Risks Varies Across Severity of Heart Failure Symptoms2019 · 24 citations